Cytokinetics, Inc.

Astellas Pharma Gmbh

Nippon Steel Corporation

Comentis, Inc.

Yasuhiro Shiina

Bradley Paul Morgan

Hiroaki Tanaka

Pu-Ping Lu

Fady Malik

Luke W Ashcraft

Takashi Kamikubo

Scott E Collibee

Masanori Miura

Jeffrey Warrington

Tomoyuki Saito

Susumu Yamaki

Ippei Sato

Yuji Matsushima

Kayoko Mihara

Marc Andrew Garard

Hiroshi Kiyohara

Munemichi Ohe

Makoto Inoue

Shingo Yamasaki

Masahiro Noguchi

Hisao Hamaguchi

Ryosuke Munakata

Kiyohiro Samizu

Hiroaki Tominaga

Lin Hong

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Tetrahydroisoquinoline derivatives

The present invention provides a hydrate of N-[(4S)-2-amino-2',2&#x2032;-dimethyldispiro[1,3-oxazole-4,4&#x2032;-chromene-3&#x2032;,3&#x2033;-oxetan]-6&#x2032;-yl]-5-chloropyridine-2-carboxamide which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by &#x3b2;-secretase activity, hydrolysis of a &#x3b2;-secretase site of a &#x3b2;-amyloid precursor protein, and/or &#x3b2;-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.

Chromane compounds

A management apparatus has a structure definition input unit for inputting the structure definition of information, a data definition input unit for inputting a data definition that represents entities of information and the relationship between the entities in accordance with the input structure definition, and a modeling unit for interpreting the input definitions and constraints to convert them into an ER model. Since an ER model can be obtained independently of the formats of input definitions, a user can freely define the structure of information as he or she likes regardless of the complexity of the structure, and need not relate information bidirectionally, and can freely and easily defines the structure of information.

Control apparatus of structured information and method of controlling the information

Growing community of inventors

Tokyo, Japan

Yasuhiro Shiina